Fig. 2.

Representative low-apparent diffusion coefficient (ADC) lesion. Axial fluid-attenuated inversion recovery (FLAIR) (A) contrast T1-weighted, (B) diffusion-weighted imaging, (C) and ADC ,(D) images at first post-bevacizumab scan and corresponding images at second post-bevacizumab scan (E-H). Representative glioblastoma showing a small enhancing lesion in the left peritrigonal region with low-ADC signal (arrow, D). Two months later, the peritrigonal lesion shows increased low-ADC volume (H) There is also mild ill-defined peripheral enhancement, which is typical with antiangiogenic therapy (low arrow, F), and multifocal enhancing lesions in the anterior corpus callosum and frontal lobes (double arrows, F) that did not show low-ADC signal. The peritrigonal lesion had a 93% increase in low-ADC volume, and the patient expired 2.1 months after the second scan.